Literature DB >> 2111109

Efficient management of diarrhea in the acquired immunodeficiency syndrome (AIDS). A medical decision analysis.

J F Johanson1, A Sonnenberg.   

Abstract

STUDY
OBJECTIVE: To compare the efficacy and cost effectiveness of alternative strategies for the evaluation and medical management of diarrhea in patients with the acquired immunodeficiency syndrome (AIDS).
DESIGN: Medical decision analysis using a decision tree.
METHODS: Three management strategies were compared: full evaluation, which included stool culture, ova and parasite examination, stain for protozoa, blood cultures, esophagogastroduodenoscopy with biopsy, and colonoscopy with biopsy; limited evaluation, which included stool culture, ova and parasite examination, stool stain for protozoa, and blood cultures; and minimal evaluation, which included only a stool culture. Treatment was based on the outcome of the diagnostic workup. Patients without a specific diagnosis were treated symptomatically with diphenoxylate hydrochloride. Nonrespondents to initial symptomatic treatment and patients with recurrent diarrhea after specific therapy were given the full evaluation. Average probabilities of diagnostic and therapeutic success were calculated from previous reports. Costs were compiled based on diagnostic and therapeutic expenditures.
MEASUREMENTS AND MAIN RESULTS: Under baseline assumptions, the remission rates for diarrhea were 75.2%, 74.8%, and 74.8% in patients undergoing the full, limited, and minimal evaluations, respectively. The respective costs of the three strategies were $5419, $1997, and $1700 per patient in remission. A sensitivity analysis showed that the differences in efficacy and cost among the full, limited, and minimal strategies remained unchanged over a broad range of possible rates of diagnostic or therapeutic success.
CONCLUSIONS: The minimal evaluation in all patients, with the full evaluation reserved only for nonrespondents to symptomatic treatment, is efficacious and is the most cost-effective strategy for managing AIDS-related diarrhea.

Entities:  

Mesh:

Year:  1990        PMID: 2111109     DOI: 10.7326/0003-4819-112-12-942

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

1.  Etiology and evaluation of diarrhea in AIDS:a global perspective at the millennium.

Authors:  C Mel Wilcox
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  Criterion-related validity of a diarrhea questionnaire in HIV-infected patients.

Authors:  Nathan M Thielman; Philip F Rust; Richard L Guerrant
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 3.  Clinical management of the complications of HIV infection.

Authors:  T G Cooney
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

4.  Investigation of chronic diarrhoea in acquired immunodeficiency syndrome. A prospective study of 155 patients.

Authors:  C Blanshard; N Francis; B G Gazzard
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

5.  Culture of intestinal biopsy specimens and stool culture for detection of bacterial enteropathogens in patients infected with human immunodeficiency virus. The Berlin Diarrhea/Wasting Syndrome Study Group.

Authors:  O Liesenfeld; T Schneider; W Schmidt; J Sandforth; T Weinke; M Zeitz; E O Riecken; R Ullrich
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

Review 6.  HIV enteropathy--a challenge in diagnosis and management.

Authors:  S J Antony
Journal:  J Natl Med Assoc       Date:  1994-05       Impact factor: 1.798

7.  Infectious Enteritis.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-04

Review 8.  Evaluation of diarrhea in HIV-infected patients.

Authors:  D Simon
Journal:  Gastrointest Endosc Clin N Am       Date:  1998-10

Review 9.  Gastrointestinal manifestations of HIV infection.

Authors:  D Sharpstone; B Gazzard
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.